Significance
G protein-coupled receptors (GPCRs) are targeted by a large fraction of approved drugs and regulate many important cellular processes. Conventional signaling by GPCRs is triggered when agonist-activated receptors associate with heterotrimeric G proteins. We found that serotonin 5-HT7 receptors couple to Gs proteins in an unconventional manner, in which agonist binding instead promotes dissociation of preexisting inactive 5-HT7–Gs complexes. Therefore, agonists can initiate signaling via two distinct mechanisms, by promoting the association of active receptors and G proteins and by promoting dissociation of inactive receptors and G proteins.
Keywords: GPCR, G protein, ternary complex, precoupling, serotonin
Abstract
Agonist binding promotes activation of G protein-coupled receptors (GPCRs) and association of active receptors with G protein heterotrimers. The resulting active-state ternary complex is the basis for conventional stimulus-response coupling. Although GPCRs can also associate with G proteins before agonist binding, the impact of such preassociated complexes on agonist-induced signaling is poorly understood. Here we show that preassociation of 5-HT7 serotonin receptors with Gs heterotrimers is necessary for agonist-induced signaling. 5-HT7 receptors in their inactive state associate with Gs, as these complexes are stabilized by inverse agonists and receptor mutations that favor the inactive state. Inactive-state 5-HT7–Gs complexes dissociate in response to agonists, allowing the formation of conventional agonist–5-HT7–Gs ternary complexes and subsequent Gs activation. Inactive-state 5-HT7–Gs complexes are required for the full dynamic range of agonist-induced signaling, as 5-HT7 receptors spontaneously activate Gs variants that cannot form inactive-state complexes. Therefore, agonist-induced signaling in this system involves two distinct receptor-G protein complexes, a conventional ternary complex that activates G proteins and an inverse-coupled binary complex that maintains the inactive state when agonist is not present.
G protein-coupled receptors (GPCRs) transduce a wide variety of physiological signals and are targeted by a substantial fraction of all therapeutic drugs (1). GPCRs are conformationally dynamic and transition between inactive and active states, the latter being capable of interacting with and activating heterotrimeric G proteins (2). Although some level of constitutive activity is common, the conformational equilibrium “setpoint” usually favors the inactive state of the receptor, thus keeping the system turned off and ready to respond to agonists. Agonist binding stabilizes active conformations and promotes the formation of transient active-state ternary agonist-receptor-G protein complexes (3). This positive allosteric interaction between agonist and G protein binding is the hallmark of conventional GPCR coupling. Receptor-G protein complexes that form before agonist binding have also been described (4–8) and are generally thought of as a means to promote rapid or specific signaling after agonist binding. However, the properties and functional significance of such “preassociated” complexes are largely unknown, and inactive receptor conformations are generally considered unable to interact with G proteins. Here we show that unliganded 5-HT7 serotonin receptors form complexes with Gs heterotrimers, and that these complexes help maintain the receptor in an inactive state. Agonist binding leads to dissociation of inactive-state 5-HT7–Gs complexes, which in turn allows increased formation of active-state 5-HT7–Gs complexes and G protein activation. Thus, a negative allosteric interaction between agonist and G protein binding is required for the full sensitivity of these receptors to serotonin.
Results
Agonist Activation Leads to Net Dissociation of Preassociated 5-HT7–Gs Complexes.
5-HT7 serotonin receptors activate Gs heterotrimers to stimulate adenylyl cyclase (AC) (9, 10), and previous work has shown that these receptors form complexes with Gs before agonist binding (11–13). We set out to determine the impact of 5-HT7–Gs preassociation on agonist-induced activation of Gs and signaling. Consistent with previous fluorescence studies (13), stimulation with serotonin (5-HT; Fig. 1A) decreased bioluminescence resonance energy transfer (BRET) between labeled 5-HT7 receptors and Gs heterotrimers. This is unusual, as energy transfer between GPCRs and G proteins usually increases in response to agonist activation (14) owing to formation of active-state receptor-G protein complexes (e.g., β2 adrenergic receptors [β2AR]) (Fig. 1A).
Fig. 1.
5-HT7–Gs complexes dissociate in response to agonist stimulation. (A) In intact cells, BRET between 5-HT7-Rluc8 and Gαsβγ-Venus decreases in response to agonist (5-hydroxytryptamine; 10 μM; n = 20), whereas BRET between β2AR-Rluc8 and Gαsβγ-Venus increases in response to agonist (isoproterenol; 10 μM; n = 20). (B) Luciferase complementation between 5-HT7-SmBit and Gαsβγ-LgBit decreases in response to agonist (5-HT; n = 20), whereas luciferase complementation between β2AR-SmBit and Gαsβγ-LgBit increases in response to agonist (Iso; n = 16). (C) Iso-induced luciferase complementation between β2AR-SmBit and Gαsβγ-LgBit is blunted when 5-HT7 receptors are coexpressed, and this is alleviated by stimulation with 5-HT (n = 14). (D and E) Similar to A, (F) similar to C, but in permeabilized cells under conditions in which Gs cannot be activated, treated with either apyrase and 100 μM GDPβS (D and F; n = 16 and 22) or apyrase alone (E, n = 8 to 12). The responses shown in D and E recovered on the addition of inverse agonists (MT and ICI-118,551; 10 μM). Traces represent mean ± SD.
To determine whether 5-HT prompted dissociation of 5-HT7–Gs complexes or a change in complex conformation, we took a luciferase complementation approach (15) that reports protein association and dissociation more directly than energy transfer. We fused a small fragment of luciferase (SmBit) to the C terminus of each receptor and a large fragment of luciferase (LgBit) to the N terminus of Gγ2 and expressed these proteins with Gαs and Gβ1. Luciferase activity decreased on stimulation of 5-HT7-SmBit but increased on stimulation of β2AR-SmBit (Fig. 1B), consistent with net dissociation and association of receptor-Gs complexes, respectively. Changes in luminescence occurred more slowly than corresponding changes in BRET, presumably due to the slow kinetics of luciferase fragment association and dissociation (15). In these experiments, Gβγ was labeled instead of the Gαs subunit so as to minimize interference with normal G protein function and receptor-G protein interactions. This left open the possibility that Gαs subunits remained associated with 5-HT7 receptors after agonist activation. To address this, we used a competition strategy in which luciferase complementation between β2AR receptors and Gs heterotrimers was monitored in the presence and absence of unlabeled 5-HT7 receptors. Expression of 5-HT7 receptors inhibited agonist-induced association of β2AR-SmBit and Gαβγ-LgBit, consistent with sequestration of Gs by 5-HT7 (12). This inhibition was relieved by stimulation with 5-HT (Fig. 1C), indicating that agonist activation of 5-HT7 made more Gs heterotrimers available to other GPCRs.
We next tested the hypothesis that preassociated 5-HT7-Gs complexes dissociate in response to agonist because Gs binds GTP and becomes activated. Accordingly, we repeated the above experiments in permeabilized cells in the absence of GTP. To eliminate the possibility that residual GTP was present, we used apyrase to hydrolyze endogenous nucleotides and replaced them with either the hydrolysis-resistant analog GDPβS or no nucleotide at all. Agonist-induced BRET changes were retained under these conditions (Fig. 1 D and E), although the 5-HT–induced decrease was blunted in the absence of any nucleotide. Since active-state agonist-GPCR-G protein complexes are stabilized in the absence of guanine nucleotides (2, 16), it is likely that 5-HT promoted both the dissociation of preassociated 5-HT7–Gs complexes and the formation of conventional active-state complexes, resulting in a smaller net dissociation when nucleotides are absent. In contrast, the agonist-induced increase in BRET between β2AR and Gs was larger in the absence of nucleotides (Fig. 1E), consistent with only active-state complexes. Sequestration and agonist-induced release of Gs heterotrimers by 5-HT7 receptors was also observed in the absence of GTP (Fig. 1F). These results indicate that agonist-induced dissociation of preassociated 5-HT7–Gs complexes does not require Gs activation.
5-HT7 Receptors in Their Inactive State Preassociate with Gs.
GPCRs are conformationally dynamic and can sample intermediate states between the fully inactive and active states. To assess the conformational state of 5-HT7 receptors when preassociated with Gs heterotrimers, we first applied inverse agonists, which stabilize the inactive state of GPCRs. Several 5-HT7 inverse agonists produced small but significant increases in BRET between 5-HT7 receptors and Gs heterotrimers (Fig. 2A). Similarly, in pull-down assays, we also found that detergent-solubilized 5-HT7 receptors retained Gs more efficiently in the presence of an inverse agonist (methiothepin [MT]) than in the presence of an agonist (5-HT) if GDP was present, whereas this was not the case for solubilized β2AR (SI Appendix, Fig. S1). These results with inverse agonists suggest that 5-HT7 receptors in their inactive state associate with Gs.
Fig. 2.
Inactive-state 5-HT7 receptors form complexes with and sequester Gs heterotrimers. (A) Agonists (blue) decrease and inverse agonists (red) increase BRET between 5-HT7-Rluc8 and Gαsβγ-Venus. BRET changes relative to vehicle controls (ΔBRET) were all significantly different from 0; P < 0.01, one-sample t test, n = 4 to 9. All ligands were tested at 10 μM with the exception of tryptamine and SB-258719 (100 μM). (B) Introduction of inactivating mutations in 5-HT7 (N380K and F336R) increases basal BRET, whereas introduction of an activating mutation (L173A) decreases basal BRET between 5-HT7-Rluc8 and Gαsβγ-Venus. Data are mean ± SD; n = 4 to 5. P < 0.05, one-way ANOVA (Dunnett’s test). (C) Inactivating and activating mutations prevent the 5-HT–induced decrease in BRET, whereas only inactivating mutations prevent the MT-induced increase in BRET between 5-HT7-Rluc8 and Gαsβγ-Venus (n = 4 to 5). (D) Inactive mutant 5-HT7 receptors abolish β2AR receptor-mediated activation of AC, whereas active mutant 5-HT7 receptors constitutively activate AC. cAMP was measured in intact cells using an EPAC-based BRET sensor that indicates increases in cAMP with lower BRET. Data are mean ± SEM; n = 5. (E) Activation of unlabeled β2AR in the absence of nucleotides decreases BRET between 5-HT7-Rluc8 and Gαsβγ-Venus, and the decrease occurs more slowly when the inverse agonist MT is present than when the agonist 5-HT is present (both at 10 μM). Traces represent normalized BRET and are the average of 24 (MT) or 28 (5-HT) replicates from three independent experiments, superimposed with fits to a two-component exponential decay. Fitted parameters are provided in SI Appendix, Table S1.
To further test this idea, we introduced mutations to produce constitutively inactive (CIM) and active (CAM) 5-HT7 receptors. For CIM receptors, residues F3366×44 and N3807×49 were mutated individually to positively charged residues, in both cases to promote interactions with D1272×50 that stabilize the inactive state. To produce a CAM receptor residue, L1733×43 was mutated to alanine to weaken hydrophobic interactions with residues in transmembrane helix 6 and promote activation. We have previously shown that both of these CIM receptors fail to support the activation of Gs and AC, whereas the CAM receptor activates Gs and AC spontaneously (17). Basal BRET between both CIM 5-HT7 receptors and Gs was significantly increased compared with wild-type (WT) 5-HT7, and ligand-induced changes in BRET were abolished. In contrast, basal BRET between the CAM 5-HT7 receptor and Gs was significantly decreased compared with WT 5-HT7, and the agonist-induced decrease was occluded (Fig. 2 B and C). These results suggested that CIM 5-HT7 receptors should efficiently sequester Gs heterotrimers, whereas CAM 5-HT7 should activate Gs. As expected, CIM 5-HT7 receptors completely prevented β2AR-mediated activation of AC, whereas CAM 5-HT7 constitutively activated AC (Fig. 2D). We also found that expression of CIM 5-HT7 significantly inhibited the ability of forskolin to activate AC (SI Appendix, Fig. S2). A similar effect has been described for inverse-agonist–bound 5-HT7 receptors (18), although the underlying mechanism is unclear. Forskolin binds directly to AC, but its actions are highly synergistic with Gαs (19, 20), and Gs is required for potent forskolin-induced AC activation in HEK 293 cells (21, 22). Therefore, inhibition of forskolin action is consistent with efficient sequestration of Gs heterotrimers by inactive 5-HT7 receptors.
We then assessed the relative stability of inactive- and active-state 5-HT7–Gs complexes with a competition experiment in which BRET between 5-HT7 and Gs was monitored during activation of unlabeled β2AR (Fig. 2E). This experiment was carried out in the absence of nucleotides to enable efficient recruitment of Gs heterotrimers by active β2AR. In the presence of MT, β2AR activation caused a biphasic decrease in BRET between 5-HT7 and Gs (kfast = ∼0.2 s−1; kslow = ∼0.03 s−1; 48% fast) (SI Appendix, Table S1), consistent with a transient association of inactive 5-HT7 and Gs under these conditions. However, in the presence of 5-HT, β2AR activation caused an even more rapid decrease in BRET between 5-HT7 and Gs (kfast = ∼0.5 s−1; kslow = ∼0.03 s−1; 83% fast). This rapid decrease started from a lower baseline due to 5-HT–induced dissociation of inactive-state complexes, but nonetheless demonstrates the existence of active-state 5-HT7–Gs complexes in the presence of 5-HT. Similar kinetic results were obtained with CIM and CAM 5-HT7 mutants (SI Appendix, Table S1). These results suggest that even in the absence of nucleotides, inactive-state 5-HT7–Gs complexes are more stable than active-state 5-HT7–Gs complexes in cell membranes, and are consistent with agonist-induced net dissociation under the same conditions (Fig. 1E).
5-HT7 Readily Adopts the Active State.
We next examined the interaction of 5-HT7 receptors with mini Gs (mGs) proteins, as these engineered Gα subunits were designed to stabilize the active state of Gs-coupled GPCRs (23). We found that unliganded 5-HT7 receptors spontaneously recruited mGs proteins to the plasma membrane, as assessed by both confocal imaging (Fig. 3 A and B) and BRET assays (Fig. 3C). Moreover, 5-HT7 interactions with mGs were only weakly sensitive to agonists or inverse agonists but in a manner opposite to that observed with Gs heterotrimers; the association of 5-HT7 and mGs was modestly enhanced by 5-HT and inhibited by MT (Fig. 3C). Similar results were obtained in pull-down assays with detergent-solubilized 5-HT7 receptors and mGs (SI Appendix, Fig. S1). Consistent with these observations, CIM 5-HT7 receptors lost the ability to interact with mGs, whereas the CAM 5-HT7 receptors retained this ability (SI Appendix, Fig. S3). These results suggest that mGs is unable to form complexes with inactive 5-HT7 that are analogous to inactive-state 5-HT7-–Gs complexes, whereas active 5-HT7 can form complexes with mGs. Furthermore, spontaneous association with mGs implies that 5-HT7 receptors readily adopt an active state in the absence of an agonist. This was not the case for β2AR, which required agonist activation for robust association with mGs under similar conditions (Fig. 3 A–C).
Fig. 3.
Unliganded and active 5-HT7 receptors bind mGs proteins. (A) Confocal images of cells expressing SNAP-tagged 5-HT7 or β2AR labeled with BG-649-PEG-biotin and NES-Venus-mGs, before and after the addition of 10 μM 5-HT or isoproterenol. (Scale bars: 20 μm.) (B) Line profiles of fluorescence intensity drawn normal to the plasma membrane from experiments as in A. Data are mean ± SEM; n = 32–45 cells. (C) BRET between Nluc-mGs and the plasma membrane marker Venus-kRas in cells expressing 5-HT7 or β2AR receptors as a function of agonist or inverse agonist concentration. Data are mean ± SEM; n = 5.
Most GPCRs intrinsically favor inactive conformations (2), and high-affinity agonist binding is usually not evident unless a nucleotide-free G protein (or a G protein surrogate) is present to stabilize the active state. An unusual characteristic of 5-HT7 receptors is a high-affinity agonist binding that persists even in the presence of guanine nucleotides (24–26). This could reflect either stabilization of active 5-HT7 by nucleotide-bound Gs (25) or, alternatively, an intrinsic tendency of the receptor to adopt active states even when Gs is not present. To test these alternatives, we performed [3H]SB269970 competitive binding assays using membranes prepared from gene-edited cells that do not express Gαs family subunits, with and without the expression of exogenous Gαs. We found that high-affinity agonist binding was maintained even in the complete absence of Gs (Fig. 4A) and was unaffected by addition of guanine nucleotides (Fig. 4B). As has been described previously (25, 27), we also observed a small population of low-affinity agonist-binding sites, and the fraction of low-affinity sites was modestly larger when Gs was present (∼30%) than when Gs was absent (∼20%) (SI Appendix, Table S2). The affinity of the inverse agonist [3H]SB269970 was slightly higher when Gs was present (Fig. 4C). These results are consistent with the suggestion that 5-HT7 receptors readily adopt active states that bind agonist with high affinity even in the absence of Gs, and further suggest that Gs may stabilize an inactive state that binds agonists with low affinity.
Fig. 4.
High-affinity agonist binding to 5-HT7 does not require Gs. (A) Competitive binding assays between the inverse agonist [3H]SB269970 and 5-HT using membranes prepared from cells lacking endogenous Gαs subunits, with or without coexpression of exogenous Gαs in the presence of 100 μM GDP. Data are mean ± SD; n = 6 to 9. Least squares fits to one- and two-site binding models are superimposed. (B) As in A but with coexpression of Gαs and in the presence of no added nucleotide or 100 μM GTPγS. Data are mean ± SD; n = 6 to 9. (C) Homologous competitive binding with unlabeled SB269970 with or without expression of Gαs. Data are mean ± SEM; n = 3. (D) Agonist binding to the activated mutant 5-HT7 L173A is similar to high-affinity binding to WT 5-HT7, whereas agonist binding to the inactive mutant 5-HT7 F336R is severely impaired. Data are mean ± SEM; n = 3. (E) Inverse agonist binds to the inactive mutant 5-HT7 F336R with higher affinity than for the active L173A mutant. Data are mean ± SEM; n = 3. Grouped data from all radioligand-binding experiments are provided in SI Appendix, Tables S2–S4.
Because most GPCRs intrinsically favor inactive conformations, the pharmacologic properties of receptors in the absence of nucleotide-free G proteins or surrogates are thought to reflect primarily the inactive state. Accordingly, agonist-binding affinity under these conditions is relatively low and is only modestly decreased by mutations that inhibit constitutive receptor activity (17), but is significantly increased by mutations that activate constitutive activity (28). However, we found that the CIM 5-HT7 F336R displayed >10,000-fold lower agonist-binding affinity than WT 5-HT7 receptors (Fig. 4D). In contrast, the CAM 5-HT7 L173A displayed agonist binding similar to the high-affinity binding component of WT 5-HT7 receptors (Fig. 4D and SI Appendix, Table S3). As expected, inverse-agonist–binding affinity was higher for CIM 5-HT7 receptors than for CAM 5-HT7 receptors (Fig. 4E). Therefore, inactive mutant 5-HT7 receptors that bind Gs tightly bind 5-HT with low affinity, whereas active mutant 5-HT7 receptors that bind Gs weakly bind 5-HT with high affinity. These results are consistent with a negative allosteric interaction between agonist and Gs binding to WT 5-HT7 receptors and a net dissociation of 5-HT7–Gs complexes on agonist binding.
Inactive-State 5-HT7–Gs Complexes Prevent Constitutive Signaling.
The foregoing results suggested that inactive- and active-state 5-HT7 receptors form distinct complexes with Gs heterotrimers. Because the C terminus of the Gα subunit is required for active-state GPCR-G protein complexes (29), we guessed that by altering this region, it might be possible to prevent formation of active-state complexes without impairing inactive-state complexes. However, removing a single amino acid from the distal C terminus of Gαs (Gαs Δ1) decreased the basal BRET between 5-HT7 and Gs, which partially occluded the agonist-induced decrease and enhanced the inverse agonist-induced increase (Fig. 5 A and B and SI Appendix, Fig. S4 A and B). Removing two amino acids (Gαs Δ2) reduced the basal BRET to background levels and converted the agonist-induced decrease observed in the presence of apyrase into an increase, implying net receptor-G protein association. Therefore, truncation of the Gαs C terminus was in fact more effective at disrupting inactive-state 5-HT7–Gs complexes and left active-state complexes at least partially intact. By comparison, the same truncations had no effect on the basal BRET between β2AR and Gs (Fig. 5C) and progressively inhibited agonist-induced coupling of β2AR to Gs (Fig. 5D and SI Appendix, Fig. S4 C and D), again suggesting that these receptors form only active-state complexes with Gs.
Fig. 5.
Truncation of the Gαs C terminus disrupts inactive-state 5-HT7-Gs complexes and leads to constitutive activation of AC. (A) Basal BRET between 5-HT7-Rluc8 and Gαsβγ-Venus in the presence of GDP decreases as the Gαs C terminus is truncated by one to four amino acids (Δ1–Δ4) or when no Gα (−) is expressed (n = 5). (B) Agonist-induced decreases in BRET between 5-HT7-Rluc8 and Gαsβγ-Venus are occluded when Gαs is truncated; ΔBRET(5-HT-MT) is BRET in 5-HT minus BRET in MT (n = 13). (C) Basal BRET between β2AR-Rluc8 and Gαsβγ-Venus does not change when Gαs is truncated (n = 5). (D) Agonist-induced increases in BRET between β2AR-Rluc8 and Gαsβγ-Venus are diminished when Gαs is truncated. ΔBRET(Iso-ICI) is BRET with isoproterenol minus BRET with ICI-118,551 (n = 11). (E) Nucleotide-sensitive BRET between 5-HT7-Rluc8 and Gαsβγ-Venus increases when Gαs is truncated (n = 5). (F) Nucleotide-sensitive BRET (basal BRET with apyrase minus basal BRET with GDP) between β2AR-Rluc8 and Gαsβγ-Venus decreases when Gαs is truncated (n = 5). Experiments in A–F were performed in permeabilized cells in the presence of GDP (100 μM) or apyrase. Data are mean ± SD. (G) Basal cAMP (control) increases in cells expressing 5-HT7 receptors when Gαs is truncated, occluding 5-HT–induced cAMP responses (n = 5). In all groups, cAMP was further increased by forskolin (Fsk), indicating that the sensor was not saturated. (H) Basal cAMP and Iso-induced cAMP responses decrease in cells expressing β2AR receptors when Gαs is truncated (n = 5). In G and H, boxes represent the 25th to 75th percentiles, whiskers indicate the maximum and minimum, and individual data points are superimposed. All experiments were carried out using cells lacking endogenous Gαs subunits.
Because the last two amino acids of Gαs are leucine residues, we suspected that hydrophobicity in this region was necessary for the inactive-state interaction with 5-HT7. Consistent with this notion, mutation of the last amino acid (Leu394) to isoleucine preserved the behavior of WT Gαs, whereas mutations of Leu394 to polar residues (Gln, Arg, or Glu) virtually abolished the inactive-state interaction with 5-HT7 (SI Appendix, Figs. S5 and S6). Gαs Leu394Ile also interacted with β2AR normally, whereas Leu394Gln, Leu394Arg, and Leu394Glu showed modest impairment of agonist-induced coupling comparable to that observed with truncated Gαs (SI Appendix, Figs. S5 and S6).
During these experiments, we noticed that nucleotide depletion with apyrase significantly enhanced the basal BRET (when no ligand was present) between 5-HT7 and Gs when Gαs subunits were truncated; nucleotide sensitivity peaked at Gαs Δ2 and declined back to baseline (WT) by Gαs Δ4 (Fig. 5E). This was not observed with β2AR (Fig. 5F), suggesting that 5-HT7 (but not β2AR) was spontaneously forming active-state complexes with truncated nucleotide-free heterotrimers. This in turn implied that 5-HT7 should constitutively activate truncated mutants. Indeed, in cells expressing 5-HT7, basal cAMP levels increased when Gαs was truncated, peaking at Gαs Δ2 and declining back to baseline by Gαs Δ4 (Fig. 5G). Stimulation with 5-HT produced only modest further increases in cAMP when Gαs was truncated, even though the AC activator forskolin could produce large further increases (Fig. 5G and SI Appendix, Fig. S7). These trends were not due to changes in spontaneous nucleotide release or hydrolysis, as truncation of Gαs progressively inhibited basal and agonist-stimulated cAMP accumulation mediated by β2AR receptors (Fig. 5H), mirroring the progressive impairment seen in direct coupling assays. 5-HT7 (but not β2AR) also constitutively activated heterotrimers with polar residues in position 394 of Gαs, and agonist-induced activation was occluded (SI Appendix, Fig. S5). Therefore, 5-HT7 receptors constitutively activated Gs heterotrimers with which they were unable to form inactive-state complexes, again consistent with a tendency of these receptors to adopt active conformations even when not bound by agonist.
Discussion
Taken together, our results support a model wherein agonist binding to 5-HT7 receptors is linked to Gs activation in a manner distinct from conventional GPCR-G protein coupling (Fig. 6A). We propose a model wherein 5-HT7 receptors in their basal state (Rn) reversibly form encounter complexes (RnG) with Gs heterotrimers. RnG encounter complexes can transition to conventional active-state complexes (RaG) but are more likely to transition to inactive-state complexes (RiG), a process we term “inverse coupling.” Constitutive Gs activation occurs through the RaG coupling pathway but is kept in check by accumulation of RiG. Agonist binding does not change the rates governing the formation of RnG encounter complexes or RaG active-state complexes, but does decrease the accumulation of RiG complexes. This decreases the net 5-HT7–Gs association and allows for increased formation of RaG and Gs activation. Our data suggest that the conformational transitions between RnG and RiG are sensitive to agonist binding to the receptor but less sensitive to nucleotide binding to Gs, whereas the conformational transitions between RnG and RaG are sensitive to nucleotide binding to Gs but less sensitive to agonist binding to the receptor. If the RnG-to-RiG pathway is blocked (e.g., by truncation or mutation of Gs), RaG complexes form spontaneously even in the absence of agonist, because the basal state of 5-HT7 intrinsically favors active conformations (Rn ∼ Ra). In contrast, conventional GPCRs in their basal state intrinsically favor inactive conformations (Rn ∼ Ri), but RiG complexes do not form or accumulate (Fig. 6A). Conventional RnG encounter complexes either dissociate or progress to RaG, and conformational transitions between RnG and RaG are sensitive to both agonist binding to the receptor and nucleotide binding to the G protein.
Fig. 6.
An inverse coupling model describes the unconventional properties of 5-HT7 receptors. (A) Inverse and conventional coupling models describing the formation of encounter complexes (RnG), active-state complexes (RaG), and inactive-state complexes (RiG). Boxes indicate rates that are influenced by agonist binding to the receptor and nucleotide binding to the G protein. (B) Simulations based on ODE models corresponding to A recapitulating net dissociation of receptor-G protein complexes for 5-HT7 but not for β2AR in response to agonist (Top), but increases in RaG complexes in intact cells for both (Bottom). (C) Simulated curves plotting normalized [Gs-GTP] vs. [5-HT] across a 200-fold increase in 5-HT7 expression (Left) and plots of simulated pEC50 vs. receptor expression for both 5-HT7 and β2AR (Right). Model parameters and conditions are provided in SI Appendix, Table S5.
Based on these general principles, we defined a set of ordinary differential equations to construct deterministic models of conventional and inverse coupling (SI Appendix, Table S5). Simulations based on these models recapitulated the essential features of receptor-G protein association, dissociation, and activation that we observed for β2AR and 5-HT7 receptors. Specifically, agonist binding led to a net association of β2AR and Gs and a net dissociation of 5-HT7 and Gs in either the presence or absence of guanine nucleotides, but increased formation of RaG (and thus Gs-GTP) in intact cells (Fig. 6B). Notably, our inverse coupling model also predicts that increasing 5-HT7 receptor density will not lead to higher potency signaling; that is, a receptor reserve will not be apparent (Fig. 6C). The absence of a receptor reserve has been observed experimentally for 5-HT7 (11), and several studies have reported lower agonist potency than expected based on agonist-binding affinity (9, 11, 27, 30). Our model suggests that this anomalous property of 5-HT7 receptors reflects sequestration of Gs heterotrimers in RiG complexes when agonist concentrations are below the level at which receptors are saturated.
Our model predicts that Gs heterotrimers should decrease agonist-binding affinity at 5-HT7 receptors by stabilizing the inactive receptor state. Although we and others have observed a small population of low-affinity agonist-binding sites (25, 27), this fraction was only modestly increased when Gs was present (Fig. 4A). It is possible that negative allostery between agonist and Gs binding is difficult to observe in equilibrium-binding experiments due to the transient nature of inactive-state 5-HT7–Gs complexes (Fig. 2E), as well as possible loss of Gs from membrane preparations. A similar problem exists for some active-state GPCR-G protein complexes, as high-affinity agonist binding can be difficult to detect for some receptors in some expression systems (31). Strategies that have been successful in stabilizing active-state complexes for ligand-binding experiments (32) may eventually be able to reveal more robust Gs-mediated inhibition of agonist binding to 5-HT7 receptors.
In summary, our present results explain several unusual biophysical and pharmacologic properties of 5-HT7 receptors. We propose that this receptor intrinsically favors active conformations but avoids unrestrained activation of Gs heterotrimers by forming inactive-state 5-HT7–Gs complexes. Agonist binding acts primarily to prevent the formation of unproductive 5-HT7–Gs complexes, which indirectly promotes the formation of productive complexes. Thus, a negative allosteric interaction between agonist binding and Gs association is necessary for agonist-induced 5-HT7 signaling. Recent studies have shown that the allosteric range of GPCRs is broader than previously anticipated (33). Engineered antibodies can stabilize both active and inactive receptor conformations (33–35), and the basal state (Rn in our model) represents a time-weighted average of conformational sampling. Our results suggest that G proteins can also act to stabilize both active and inactive receptor conformations and cooperate with agonist binding in both a positive and a negative manner. Although our results indicate that the distal C terminus of Gαs is required for inactive-state 5-HT7–Gs complexes, further studies are needed to establish the structural mechanism through which Gs stabilizes the inactive state of the receptor. It will be interesting to determine whether Gs acts in a manner similar to the way in which negative allosteric antibodies stabilize inactive GPCRs (33–35). Several other GPCRs are thought to interact with G proteins before agonist binding (4–8); therefore, it seems possible that inverse coupling will prove to be a conserved mechanism for regulating the sensitivity and dynamic range of cell signaling.
Materials and Methods
Materials.
Trypsin, DPBS, PBS, FBS, MEM, DMEM, penicillin/streptomycin, and l-glutamine were obtained from Thermo Fisher Scientific. Receptor ligands (5-HT, isoproterenol, ICI-118,551, and MT) and forskolin were purchased from Cayman Chemical or MilliporeSigma. Detergents (n-dodecyl-β-d-maltoside [DDM] and cholesteryl hemisuccinate [CHS]) were obtained from Anatrace. Digitonin, apyrase, GDPβS, and GDP were purchased from MilliporeSigma or BioBasic. [3H]SB269970 was obtained from PerkinElmer, and polyethylenimine (PEI) MAX was purchased from Polysciences.
Plasmid DNA Constructs.
5-HT7-Rluc8 was made by amplifying the human 5-HT7 coding sequence (splice variant d) using the PCR results for 5-HT7–Tango (36) (Roth Lab PRESTO-Tango Kit; Addgene) and ligating into pRluc8-N1 with HindIII and KpnI. Inactivating and activating mutations were introduced into 5-HT7–Rluc8 using the QuikChange Mutagenesis Kit (Agilent Technologies) and gBlock fragments (Integrated DNA Technologies) as primers. Plasmids encoding unlabeled human 5-HT7, β2AR, Gαs-long, and Gβ1 were purchased from the cDNA Resource Center. Truncated and mutated Gαs subunits were derived from WT Gαs-long by amplifying the coding sequence with reverse primers incorporating the desired mutation and ligating the resulting fragment into pcDNA3.1(+) using KpnI and XhoI. A plasmid encoding β2AR-SmBit was derived from unlabeled β2AR using the QuikChange Mutagenesis Kit and a gBlock primer. A plasmid encoding 5-HT7–SmBit was derived from unlabeled 5-HT7 by standard subcloning into a SmBit vector. A plasmid encoding LgBit-Gγ2 was kindly provided by Stephen R. Ikeda, National Institute on Alcohol Abuse and Alcoholism. A plasmid encoding the Nluc-EPAC-VV cAMP sensor was kindly provided by Kirill Martemyanov, The Scripps Research Institute. Plasmids encoding β2AR-Rluc8, NES-Venus-mGs, NES-Nluc-mGs, Venus-kras, Venus-1–155-Gγ2, and Venus-155–239-Gβ1 have been described previously (22, 37, 38). All plasmid constructs were verified by Sanger sequencing.
Cell Culture and Transfection.
HEK 293 cells (American Type Culture Collection; CRL-1573) were propagated in plastic flasks and on six-well plates according to the supplier’s protocol. HEK 293 cells with targeted deletion of GNAS and GNAL were a generous gift from Asuka Inoue, Tohoku University, and were derived, authenticated and propagated as described previously (39). Cells were transiently transfected in growth medium using linear PEI MAX (molecular weight 40,000) at a nitrogen/phosphate ratio of 20 and were used for experiments 24 to 48 h later. Up to 3.0 μg of plasmid DNA was transfected in each well of a six-well plate.
BRET and Luminescence Assays.
Intact cells were washed twice with 1× DPBS, harvested by trituration, and transferred to opaque black (for BRET) or white (for luminescence) 96-well plates. Permeabilized cells were washed twice with permeabilization buffer (KPS) containing 140 mM KCl, 10 mM NaCl, 1 mM MgCl2, 0.1 mM KEGTA, and 20 mM NaHEPES (pH 7.2); harvested by trituration; permeabilized in KPS buffer containing 10 μg mL−1 high-purity digitonin; and then transferred to 96-well plates. Measurements were made from permeabilized cells supplemented with 100 μM GDP, 2 U mL−1 apyrase, or apyrase with 100 μM GDPβS. Steady-state BRET and luminescence measurements were performed using a Mithras LB940 photon-counting plate reader (Berthold Technologies). Kinetic BRET and luminescence time course measurements were obtained with a POLARstar Optima plate reader (BMG Labtech). Coelenterazine h (5 µM; Nanolight) or furimazine (NanoGlo; 1:1,000; Promega) were added to all wells immediately before taking measurements with Rluc8 and Nluc, respectively. Raw BRET signals were calculated as the emission intensity at 520 to 545 nm divided by the emission intensity at 475 to 495 nm. Net BRET is the raw BRET ratio minus the ratio measured from cells expressing only the donor.
Confocal Imaging.
Cells grown on 25-mm round coverslips were transferred to an imaging chamber and washed with DPBS. Drug solutions were added directly to the chamber by pipetting. Confocal images were acquired using a Leica SP8 scanning confocal microscope with a 63×, 1.4 NA objective. Venus was excited with a 488-nm diode laser and detected at 500 to 650 nm. BG-649–PEG–biotin was excited with a 633-nm diode laser and detected at 640 to 750 nm.
Membrane Preparation and Radioligand Binding.
Transfected cells were washed twice with cold PBS/EDTA and resuspended in cold DPBS. After pelleting at 600 × g for 10 min at 4 °C, cells were resuspended in cold homogenization buffer containing 75 mM Tris⋅HCl pH 7.4, 2 mM EDTA, and protease inhibitor mixture (Roche). Cells were sonicated (three 5-s pulses at 20% amplitude with a 50-s cooldown period between each pulse), debris was pelleted at 500 × g for 10 min at 4 °C, and supernatants were centrifuged at 50,000 × g for 30 min at 4 °C. Pellets were resuspended in assay buffer containing 100 mM NaCl, 10 mM MgCl2, and 20 mM Hepes, pH 7.4, then snap-frozen and stored at −80 °C. Competitive binding assays were performed as described previously (26) by incubating membranes with [3H]SB269970 (2.5 to 2.8 nM) and increasing concentrations of 5-HT in 96-well plates. Plates were incubated at 23 °C for 60 min and then harvested onto UniFilter-96 GF/C microplates (PerkinElmer), presoaked in 0.3% polyethyleneimine (MilliporeSigma) using a universal harvester, and washed three to four times with ∼0.25 mL per well of ice-cold buffer containing 50 mM Tris⋅HCl pH 7.0 and 2 mM MgCl2. The filters were dried and counted at ∼40% efficiency in a TopCount liquid scintillation counter using 20 μL per well of MicroScint liquid scintillation mixture (PerkinElmer). Alternatively, cell membranes were incubated with 1 nM [3H]SB269970 and various concentrations of 5-HT or unlabeled SB269970 for 3 h at room temperature in binding buffer containing 20 mM Hepes pH 7.5, 50 mM NaCl, 1 mM EDTA, 5 mM MgCl2, and 0.1% (wt/vol) BSA (Fig. 4 C–E). After incubation, the reaction was terminated by adding cold binding buffer, followed by rapid filtering through glass fiber prefilters using a semiautomated harvester (Brandel). The filters were then washed three times with 5 mL of cold binding buffer and transferred to scintillation vials. Liquid scintillation mixture (5 mL; CytoScint; MP Biomedicals) was added on top of each filter. After overnight incubation, the radioactivity of the filters was measured with a Beckman LS6500 scintillation counter.
Pull-Down Assays.
HEK 293 cells were transiently transfected with Nluc-Gγ2, Gβ1, Gαs-long, and either SNAPf-β2AR or SNAPf-5HT7 in a 1:1:2:1 ratio or Nluc-mGs and either SNAPf-β2AR or SNAPf-5HT7 in a 2:1 ratio. After 48 h, cells were incubated with 100 nM BG-649-PEG-biotin dye (New England BioLabs) in complete growth medium for 1 h at 37 °C. After three washes with DPBS, membranes were prepared as above, with the addition of 10 μM GDP and receptor ligands (10 μM 5-HT, MT, isoproterenol, or ICI-118,551) to the homogenization buffer. Membranes were solubilized in 500 μL of solubilization buffer (20 mM Hepes pH 7.8, 150 mM NaCl, 2 mM MgCl2, 20% [vol/vol] glycerol, 1% [wt/vol] DDM, 0.2% [wt/vol] CHS, and protease inhibitor mixture [Roche]), 100 μM GDP or 2 U mL−1 apyrase, and receptor ligands as above for 3 h at 4 °C with gentle rotation. Solubilized membranes were incubated with 250 μg of streptavidin (sAV) beads (Dynabeads MyOne sAV C1; Thermo Fisher Scientific) that had been washed with wash buffer (20 mM Hepes pH 7.8, 100 mM NaCl, 2 mM MgCl2, 10% [vol/vol] glycerol, 0.1% [wt/vol] DDM, 0.02% [wt/vol] CHS, and protease inhibitor mixture) for 2.5 h at 4 °C with gentle rotation. Beads were washed five times with 1 mL of wash buffer supplemented with either 50 μM GDP or 1 U mL−1 apyrase and receptor ligands, diluted in 500 μL of working solution (20 mM Hepes pH 7.8, 100 mM NaCl, 2 mM MgCl2, 0.1% [wt/vol] DDM, and 0.02% [wt/vol] CHS) and transferred to opaque black 96-well plates. BG-PEG-SNAP-649 fluorescence was determined using a Synergy Neo2 plate reader (BioTek; excitation, 640 nm; emission, 676 nm). Furimazine (NanoGlo, 1:1,000; Promega) was added, and luminescence was measured without wavelength selection. Recovered Nluc activity (Gs or mGs) was normalized to fluorescence (receptor).
Computational Modeling.
Rule-based deterministic models of conventional and inverse coupling based on ordinary differential equations (ODE) were constructed using the Virtual Cell (VCell) modeling platform (40, 41). Initial reactions and parameters followed a previously published analytical model (42), which was modified to include three receptor states, RiG complexes (for the inverse coupling model only), and inverse agonist binding. Both models included basal (Rn), inactive (Ri), and active (Ra) receptor states, each of which could bind reversibly to agonist (La) or inverse agonist (Li). G proteins could be empty, bound to GDP, or bound to GTP and could bind reversibly to ligand-bound or unbound receptors. Reactions, parameters, and initial conditions are given in SI Appendix, Table S5). The VCell, “5HT7_Jang_2020” by user “wojang,” can be accessed within the VCell software (available at https://vcell.org).
Statistical Testing.
Hypothesis tests were carried out with the two-tailed paired t test, one-sample t test, one-way ANOVA using Dunnett’s test for multiple comparisons against a control, or two-way ANOVA using Sidak’s test for multiple comparisons, as indicated in figure legends. Replicates were separate cultures of transfected cells derived from the two cell lines used. All data were analyzed using GraphPad Prism.
Supplementary Material
Acknowledgments
We thank Aska Inoue for providing CRISPR-modified cells lacking Gαs family subunits, and Steve Ikeda, Kirill Martemyanov, and Bryan Roth for providing plasmid DNA. We also thank Najeah Okashah, Qingwen Wan, Alexey Bondar, and Sumin Lu for technical assistance and critical discussion. This study was supported by the NIH (Grants GM130142, to N.A.L. and GM128641, to C.Z.), the Norwegian Council on Cardiovascular Diseases, the South-Eastern Norway Regional Health Authority, the Anders Jahre Foundation for the Promotion of Science, the Simon Fougner Hartmann Family Foundation, the Family Blix Foundation, and the University of Oslo (to F.O.L.).
Footnotes
The authors declare no competing interest.
This article is a PNAS Direct Submission.
This article contains supporting information online at https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2010801117/-/DCSupplemental.
Data Availability.
All study data are included in the main text and SI Appendix.
References
- 1.Pierce K. L., Premont R. T., Lefkowitz R. J., Seven-transmembrane receptors. Nat. Rev. Mol. Cell Biol. 3, 639–650 (2002). [DOI] [PubMed] [Google Scholar]
- 2.Weis W. I., Kobilka B. K., The molecular basis of G protein-coupled receptor activation. Annu. Rev. Biochem. 87, 897–919 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.De Lean A., Stadel J. M., Lefkowitz R. J., A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J. Biol. Chem. 255, 7108–7117 (1980). [PubMed] [Google Scholar]
- 4.Bouaboula M., et al. , A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J. Biol. Chem. 272, 22330–22339 (1997). [DOI] [PubMed] [Google Scholar]
- 5.Monczor F., et al. , Tiotidine, a histamine H2 receptor inverse agonist that binds with high affinity to an inactive G-protein-coupled form of the receptor. Experimental support for the cubic ternary complex model. Mol. Pharmacol. 64, 512–520 (2003). [DOI] [PubMed] [Google Scholar]
- 6.Damian M., et al. , Ghrelin receptor conformational dynamics regulate the transition from a preassembled to an active receptor:Gq complex. Proc. Natl. Acad. Sci. U.S.A. 112, 1601–1606 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Kilander M. B. C., et al. , Disheveled regulates precoupling of heterotrimeric G proteins to Frizzled 6. FASEB J. 28, 2293–2305 (2014). [DOI] [PubMed] [Google Scholar]
- 8.Weiss J. M., Morgan P. H., Lutz M. W., Kenakin T. P., The cubic ternary complex receptor–Occupancy model I. Model description. J. Theor. Biol. 178, 151–167 (1996). [DOI] [PubMed] [Google Scholar]
- 9.Eglen R. M., Jasper J. R., Chang D. J., Martin G. R., The 5-HT7 receptor: Orphan found. Trends Pharmacol. Sci. 18, 104–107 (1997). [DOI] [PubMed] [Google Scholar]
- 10.Roth B. L., et al. , Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J. Pharmacol. Exp. Ther. 268, 1403–1410 (1994). [PubMed] [Google Scholar]
- 11.Bruheim S., Krobert K. A., Andressen K. W., Levy F. O., Unaltered agonist potency upon inducible 5-HT7(a) but not 5-HT4(b) receptor expression indicates agonist-independent association of 5-HT7(a) receptor and Gs. Recept. Channels 9, 107–116 (2003). [PubMed] [Google Scholar]
- 12.Andressen K. W., Norum J. H., Levy F. O., Krobert K. A., Activation of adenylyl cyclase by endogenous G(s)-coupled receptors in human embryonic kidney 293 cells is attenuated by 5-HT(7) receptor expression. Mol. Pharmacol. 69, 207–215 (2006). [DOI] [PubMed] [Google Scholar]
- 13.Andressen K. W., et al. , Related GPCRs couple differently to Gs: Preassociation between G protein and 5-HT7 serotonin receptor reveals movement of Gαs upon receptor activation. FASEB J. 32, 1059–1069 (2018). [DOI] [PubMed] [Google Scholar]
- 14.Galés C., et al. , Real-time monitoring of receptor and G-protein interactions in living cells. Nat. Methods 2, 177–184 (2005). [DOI] [PubMed] [Google Scholar]
- 15.Dixon A. S., et al. , NanoLuc complementation reporter optimized for accurate measurement of protein interactions in cells. ACS Chem. Biol. 11, 400–408 (2016). [DOI] [PubMed] [Google Scholar]
- 16.Yao X. J., et al. , The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex. Proc. Natl. Acad. Sci. U.S.A. 106, 9501–9506 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Zhou Q., et al. , Common activation mechanism of class A GPCRs. eLife 8, e50279 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Toohey N., Klein M. T., Knight J., Smith C., Teitler M., Human 5-HT7 receptor-induced inactivation of forskolin-stimulated adenylate cyclase by risperidone, 9-OH-risperidone and other “inactivating antagonists”. Mol. Pharmacol. 76, 552–559 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Sunahara R. K., Dessauer C. W., Whisnant R. E., Kleuss C., Gilman A. G., Interaction of Gsalpha with the cytosolic domains of mammalian adenylyl cyclase. J. Biol. Chem. 272, 22265–22271 (1997). [DOI] [PubMed] [Google Scholar]
- 20.Insel P. A., Ostrom R. S., Forskolin as a tool for examining adenylyl cyclase expression, regulation, and G protein signaling. Cell. Mol. Neurobiol. 23, 305–314 (2003). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Inoue A., et al. , Illuminating G-protein-coupling selectivity of GPCRs. Cell 177, 1933–1947.e25 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Okashah N., et al. , Variable G protein determinants of GPCR coupling selectivity. Proc. Natl. Acad. Sci. U.S.A. 116, 12054–12059 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Nehmé R., et al. , Mini-G proteins: Novel tools for studying GPCRs in their active conformation. PLoS One 12, e0175642 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Thomas D. R., et al. , [(3)H]-SB-269970: A selective antagonist radioligand for 5-HT(7) receptors. Br. J. Pharmacol. 130, 409–417 (2000). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Alberts G. L., Chio C. L., Im W. B., Allosteric modulation of the human 5-HT(7A) receptor by lipidic amphipathic compounds. Mol. Pharmacol. 60, 1349–1355 (2001). [DOI] [PubMed] [Google Scholar]
- 26.Krobert K. A., Bach T., Syversveen T., Kvingedal A. M., Levy F. O., The cloned human 5-HT7 receptor splice variants: A comparative characterization of their pharmacology, function and distribution. Naunyn Schmiedebergs Arch. Pharmacol. 363, 620–632 (2001). [DOI] [PubMed] [Google Scholar]
- 27.Ulsund A. H., et al. , Preassociation between the 5-HT7 serotonin receptor and G protein Gs: Molecular determinants and association with low potency activation of adenylyl cyclase. FASEB J. 33, 3870–3886 (2019). [DOI] [PubMed] [Google Scholar]
- 28.Samama P., Cotecchia S., Costa T., Lefkowitz R. J., A mutation-induced activated state of the β 2-adrenergic receptor: Extending the ternary complex model. J. Biol. Chem. 268, 4625–4636 (1993). [PubMed] [Google Scholar]
- 29.Du Y., et al. , Assembly of a GPCR-G protein complex. Cell 177, 1232–1242.e11 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Jasper J. R., Kosaka A., To Z. P., Chang D. J., Eglen R. M., Cloning, expression and pharmacology of a truncated splice variant of the human 5-HT7 receptor (h5-HT7b). Br. J. Pharmacol. 122, 126–132 (1997). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Seifert R., Lee T. W., Lam V. T., Kobilka B. K., Reconstitution of β2-adrenoceptor-GTP-binding-protein interaction in Sf9 cells: High coupling efficiency in a β2-adrenoceptor-G(s α) fusion protein. Eur. J. Biochem. 255, 369–382 (1998). [DOI] [PubMed] [Google Scholar]
- 32.Seifert R., Wenzel-Seifert K., Kobilka B. K., GPCR-galpha fusion proteins: Molecular analysis of receptor-G-protein coupling. Trends Pharmacol. Sci. 20, 383–389 (1999). [DOI] [PubMed] [Google Scholar]
- 33.Staus D. P., et al. , Allosteric nanobodies reveal the dynamic range and diverse mechanisms of G-protein-coupled receptor activation. Nature 535, 448–452 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Hino T., et al. , G-protein-coupled receptor inactivation by an allosteric inverse-agonist antibody. Nature 482, 237–240 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Che T., et al. , Nanobody-enabled monitoring of kappa opioid receptor states. Nat. Commun. 11, 1145 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Kroeze W. K., et al. , PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome. Nat. Struct. Mol. Biol. 22, 362–369 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Hollins B., Kuravi S., Digby G. J., Lambert N. A., The C terminus of GRK3 indicates rapid dissociation of G protein heterotrimers. Cell. Signal. 21, 1015–1021 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Wan Q., et al. , Mini G protein probes for active G protein-coupled receptors (GPCRs) in live cells. J. Biol. Chem. 293, 7466–7473 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Stallaert W., et al. , Purinergic receptor transactivation by the β2-adrenergic receptor increases intracellular Ca2+ in nonexcitable cells. Mol. Pharmacol. 91, 533–544 (2017). [DOI] [PubMed] [Google Scholar]
- 40.Schaff J., Fink C. C., Slepchenko B., Carson J. H., Loew L. M., A general computational framework for modeling cellular structure and function. Biophys. J. 73, 1135–1146 (1997). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Blinov M. L., et al. , Compartmental and spatial rule-based modeling with Virtual Cell. Biophys. J. 113, 1365–1372 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Sungkaworn T., et al. , Single-molecule imaging reveals receptor-G protein interactions at cell surface hot spots. Nature 550, 543–547 (2017). [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
All study data are included in the main text and SI Appendix.






